{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:05:09Z","timestamp":1787065509664,"version":"build-2736575974"},"reference-count":334,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"crossref","award":["YDZJ202201ZYTS254"],"award-info":[{"award-number":["YDZJ202201ZYTS254"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2025.2598478","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:02:16Z","timestamp":1765803736000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Antitumor activity and structure\u2013activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors"],"prefix":"10.1080","volume":"41","author":[{"given":"Chunhui","family":"Yang","sequence":"first","affiliation":[{"name":"Acupuncture and Tuina Center, The Third Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Shang","sequence":"additional","affiliation":[{"name":"Pharmacy Department, The Third Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina Center, The Third Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[{"name":"College of Integrative Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Li","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina Center, The Third Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Han","sequence":"additional","affiliation":[{"name":"College of Integrative Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"7267","key":"e_1_3_4_2_1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Ackson SP","year":"2009","unstructured":"Ackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071\u20131078.","journal-title":"Nature"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0150-x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01060-w"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115907"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00535-5"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0076-6"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2018.08.021"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01167-9"},{"issue":"1","key":"e_1_3_4_11_1","doi-asserted-by":"crossref","first-page":"W420","DOI":"10.1093\/nar\/gkac373","article-title":"IBS 2.0: an upgraded illustrator for the visualization of biological sequences","volume":"50","author":"Xie Y","year":"2022","unstructured":"Xie Y, Li H, Luo X, Li H, Gao Q, Zhang L, Teng Y, Zhao Q, Zuo Z, Ren J. IBS 2.0: an upgraded illustrator for the visualization of biological sequences. Nucleic Acids Res. 2022;50(W1):W420\u2013W426.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106162"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2023.09.005"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00865"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07217-2"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117955"},{"issue":"1","key":"e_1_3_4_17_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella A","year":"2022","unstructured":"Padella A, Ghelli Luserna Di Ror\u00e0 A, Marconi G, Ghetti M, Martinelli G, Simonetti G. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. J Hematol Oncol. 2022;15(1):10.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"e_1_3_4_18_1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed G","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42(12):2113\u20132123.e4.","journal-title":"Cancer Cell"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-031-30065-3_3","article-title":"Mechanisms of PARP inhibitor resistance","volume":"186","author":"O\u2019Connor MJ","year":"2023","unstructured":"O\u2019Connor MJ, Forment JV. Mechanisms of PARP inhibitor resistance. Cancer Treat Res. 2023;186:25\u201342.","journal-title":"Cancer Treat Res"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0212"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00532-x"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116810"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103607"},{"issue":"4","key":"e_1_3_4_24_1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley DM","year":"2023","unstructured":"O\u2019Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP inhibitors in ovarian cancer: a review. Targ Oncol. 2023;18(4):471\u2013503.","journal-title":"Targ Oncol"},{"issue":"12","key":"e_1_3_4_25_1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","article-title":"Tackling PARP inhibitor resistance","volume":"7","author":"Fugger K","year":"2021","unstructured":"Fugger K, Hewitt G, West SC, Boulton SJ. Tackling PARP inhibitor resistance. Trends Cancer. 2021;7(12):1102\u20131118.","journal-title":"Trends Cancer"},{"issue":"12","key":"e_1_3_4_26_1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1021\/acsmedchemlett.3c00458","article-title":"Novel PARP7 inhibi\u200ators for treating cancer","volume":"14","author":"Sabnis RW.","year":"2023","unstructured":"Sabnis RW. Novel PARP7 inhibi\u200ators for treating cancer. ACS Med Chem Lett. 2023;14(12):1615\u20131616.","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"e_1_3_4_27_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1021\/acsmedchemlett.3c00308","article-title":"PARP7 inhibition: a promising pathway to advancements in cancer therapy","volume":"14","author":"Kargbo RB.","year":"2023","unstructured":"Kargbo RB. PARP7 inhibition: a promising pathway to advancements in cancer therapy. ACS Med Chem Lett. 2023;14(9):1141\u20131143.","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"e_1_3_4_28_1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2174\/0929867327666200312113011","article-title":"A review on poly (ADP-ribose) polymerase (PARP) inhibitors and synthetic methodologies","volume":"28","author":"Li Y","year":"2021","unstructured":"Li Y, Liu CF, Rao GW. A review on poly (ADP-ribose) polymerase (PARP) inhibitors and synthetic methodologies. Curr Med Chem. 2021;28(8):1565\u20131584.","journal-title":"Curr Med Chem"},{"issue":"4","key":"e_1_3_4_29_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1021\/acsmedchemlett.5c00127","article-title":"Novel PARP7 inh\u200aibitors for treating cance\u200ar","volume":"16","author":"Sabnis RW.","year":"2025","unstructured":"Sabnis RW. Novel PARP7 inh\u200aibitors for treating cance\u200ar. ACS Med Chem Lett. 2025;16(4):526\u2013527.","journal-title":"ACS Med Chem Lett"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0211"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601"},{"key":"e_1_3_4_32_1","doi-asserted-by":"crossref","first-page":"1198948","DOI":"10.3389\/fphar.2023.1198948","article-title":"PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities","volume":"14","author":"Li WH","year":"2023","unstructured":"Li WH, Wang F, Song GY, Yu QH, Du RP, Xu P. PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities. Front Pharmacol. 2023;14:1198948.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1901882"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz120"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.334516.119"},{"key":"e_1_3_4_36_1","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/erm.2024.14","article-title":"Specific and shared biological functions of PARP2 - is PARP2 really a lil\u2019 brother of PARP1?","volume":"26","author":"Sz\u00e1nt\u00f3 M","year":"2024","unstructured":"Sz\u00e1nt\u00f3 M, Y\u00e9lamos J, Bai P. Specific and shared biological functions of PARP2 - is PARP2 really a lil\u2019 brother of PARP1? Expert Rev Mol Med. 2024;26:e13.","journal-title":"Expert Rev Mol Med"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.05.028"},{"key":"e_1_3_4_38_1","doi-asserted-by":"crossref","first-page":"103690","DOI":"10.1016\/j.dnarep.2024.103690","article-title":"The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication","volume":"140","author":"Zhang H","year":"2024","unstructured":"Zhang H, Zha S. The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication. DNA Repair (Amst). 2024;140:103690.","journal-title":"DNA Repair (Amst)"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20210378"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030623"},{"issue":"1","key":"e_1_3_4_41_1","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1038\/s41467-021-23055-6","article-title":"Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly","volume":"12","author":"Yang CS","year":"2021","unstructured":"Yang CS, Jividen K, Kamata T, Dworak N, Oostdyk L, Remlein B, Pourfarjam Y, Kim IK, Du KP, Abbas T, et al. Androgen signaling uses a writer and a reader of ADP-ribosylation to regulate protein complex assembly. Nat Commun. 2021;12(1):2705.","journal-title":"Nat Commun"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20180347"},{"issue":"2","key":"e_1_3_4_43_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/cells10020363","article-title":"Post-transcriptional regulation of PARP7 protein stability is controlled by androgen signaling","volume":"10","author":"Kamata T","year":"2021","unstructured":"Kamata T, Yang CS, Melhuish TA, Frierson HF, Jr, Wotton D, Paschal BM. Post-transcriptional regulation of PARP7 protein stability is controlled by androgen signaling. Cells. 2021;10(2):363.","journal-title":"Cells"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020920"},{"issue":"3","key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"e16235","DOI":"10.15252\/emmm.202216235","article-title":"Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance","volume":"15","author":"Wang LM","year":"2023","unstructured":"Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, et al. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Mol Med. 2023;15(3):e16235.","journal-title":"EMBO Mol Med"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.018"},{"issue":"6","key":"e_1_3_4_47_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11523-021-00842-1","article-title":"Olaparib: a review as first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Paik J.","year":"2021","unstructured":"Paik J. Olaparib: a review as first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 2021;16(6):847\u2013856.","journal-title":"Target Oncol"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676"},{"issue":"11","key":"e_1_3_4_49_1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk BJ","year":"2024","unstructured":"Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann Oncol. 2024;35(11):981\u2013992.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"issue":"6","key":"e_1_3_4_51_1","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.3802\/jgo.2022.33.e86","article-title":"Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective","volume":"33","author":"Li N","year":"2022","unstructured":"Li N, Liu Q, Tian Y, Wu L. Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. J Gynecol Oncol. 2022;33(6):e86.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"e_1_3_4_52_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-024-02437-2","article-title":"Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial","volume":"19","author":"Mao J","year":"2024","unstructured":"Mao J, Ni J, Chu L, Chu X, Xu D, Yang X, Zhu Z. Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial. Radiat Oncol. 2024;19(1):47.","journal-title":"Radiat Oncol"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.04.035"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450118666170711151518"},{"issue":"1","key":"e_1_3_4_56_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero A","year":"2024","unstructured":"Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Dom\u00e8nech-Viv\u00f3 J, Garc\u00eda-Galea E, Moles-Fern\u00e1ndez A, Pedretti F, Dom\u00e8nech H, Rodr\u00edguez O, Guzm\u00e1n M, et al. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models. Genome Med. 2024;16(1):107.","journal-title":"Genome Med"},{"key":"e_1_3_4_57_1","doi-asserted-by":"crossref","first-page":"116160","DOI":"10.1016\/j.ejmech.2024.116160","article-title":"Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability","volume":"266","author":"Xu J","year":"2024","unstructured":"Xu J, Zhao A, Chen D, Wang J, Ma J, Qing L, Li Y, Fang H, He H, Pan W, et al. Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability. Eur J Med Chem. 2024;266:116160.","journal-title":"Eur J Med Chem"},{"issue":"7","key":"e_1_3_4_58_1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-23-2094","article-title":"Preclinical characterization of AZD9574, a blood\u2013brain barrier penetrant inhibitor of PARP1","volume":"30","author":"Staniszewska AD","year":"2024","unstructured":"Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, et al. Preclinical characterization of AZD9574, a blood\u2013brain barrier penetrant inhibitor of PARP1. Clin Cancer Res. 2024;30(7):1338\u20131351.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.004"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0916-5"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3868"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117937"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00966-z"},{"issue":"1","key":"e_1_3_4_64_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","article-title":"Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation","volume":"13","author":"Topatana W","year":"2020","unstructured":"Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, et al. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13(1):118.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax6367"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115300"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw635"},{"issue":"21","key":"e_1_3_4_68_1","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper","volume":"28","author":"Illuzzi G","year":"2022","unstructured":"Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, et al. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022;28(21):4724\u20134736.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-472845"},{"issue":"19","key":"e_1_3_4_70_1","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1021\/acs.jmedchem.1c01012","article-title":"Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs","volume":"64","author":"Johannes JW","year":"2021","unstructured":"Johannes JW, Balazs A, Barratt D, Bista M, Chuba MD, Cosulich S, Critchlow SE, Degorce SL, Di Fruscia P, Edmondson SD, et al. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. J Med Chem. 2021;64(19):14498\u201314512.","journal-title":"J Med Chem"},{"issue":"24","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"21717","DOI":"10.1021\/acs.jmedchem.4c01725","article-title":"Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor","volume":"67","author":"Johannes JW","year":"2024","unstructured":"Johannes JW, Balazs AYS, Barratt D, Bista M, Chuba MD, Cosulich S, Critchlow SE, Degorce SL, Di Fruscia P, Edmondson SD, et al. Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor. J Med Chem. 2024;67(24):21717\u201321728.","journal-title":"J Med Chem"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00568"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116803"},{"key":"e_1_3_4_74_1","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1017\/erm.2024.13","article-title":"PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology","volume":"26","author":"Morone B","year":"2024","unstructured":"Morone B, Grimaldi G. PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology. Expert Rev Mol Med. 2024;26:e17.","journal-title":"Expert Rev Mol Med"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.01.024"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112570"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102410"},{"key":"e_1_3_4_78_1","doi-asserted-by":"crossref","first-page":"1035954","DOI":"10.3389\/fphar.2022.1035954","article-title":"Combinatorial regimens of chemotherapeutic agents: a new perspective on raising the heat of the tumor immune microenvironment","volume":"13","author":"Liu J","year":"2022","unstructured":"Liu J, Yu Y, Liu C, Gao C, Zhuang J, Liu L, Wu Q, Ma W, Zhang Q, Sun C. Combinatorial regimens of chemotherapeutic agents: a new perspective on raising the heat of the tumor immune microenvironment. Front Pharmacol. 2022;13:1035954.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_79_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-3-031-30065-3_9","article-title":"Combining poly (ADP-Ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: promise and challenges","volume":"186","author":"Thein KZ","year":"2023","unstructured":"Thein KZ, Thawani R, Kummar S. Combining poly (ADP-Ribose) polymerase (PARP) inhibitors with chemotherapeutic agents: promise and challenges. Cancer Treat Res. 2023;186:143\u2013170.","journal-title":"Cancer Treat Res"},{"key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"107534","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski R.","year":"2024","unstructured":"Roskoski R.Jr. Targeted and cytotoxic inhibitors used in the treatment of breast cancer. Pharmacol Res. 2024;210:107534.","journal-title":"Pharmacol Res"},{"issue":"15","key":"e_1_3_4_81_1","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.3390\/ijms23158125","article-title":"The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review","volume":"23","author":"Lau CH","year":"2022","unstructured":"Lau CH, Seow KM, Chen KH. The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review. Int J Mol Sci. 2022;23(15):8125.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2020.1821676"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180518074959"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2042689"},{"issue":"14","key":"e_1_3_4_85_1","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia A","year":"2024","unstructured":"Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, et al. Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res. 2024;30(14):2917\u20132924.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2572"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2018.0023"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.03.021"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1177\/1535370219867296"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-57127-0_5"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.11.033"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.014"},{"issue":"24","key":"e_1_3_4_93_1","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon P","year":"2021","unstructured":"Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Stagljar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021;40(24):4079\u20134093.","journal-title":"Oncogene"},{"key":"e_1_3_4_94_1","doi-asserted-by":"crossref","first-page":"153303382412347","DOI":"10.1177\/15330338241234780","article-title":"Targeting receptor tyrosine kinases as a novel strategy for the treatment of triple-negative breast cancer","volume":"23","author":"Jaradat SK","year":"2024","unstructured":"Jaradat SK, Ayoub NM, Al Sharie AH, Aldaod JM. Targeting receptor tyrosine kinases as a novel strategy for the treatment of triple-negative breast cancer. Technol Cancer Res Treat. 2024;23:15330338241234780.","journal-title":"Technol Cancer Res Treat"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01391-4"},{"issue":"1","key":"e_1_3_4_96_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu M","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol. 2023;16(1):94.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav4474"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134579"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2442900"},{"key":"e_1_3_4_100_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2020.09.018","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a multicenter, randomized phase II study (GOAL)","volume":"150","author":"Garcia-Campelo R","year":"2020","unstructured":"Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Spanish Lung Cancer Group (SLCG), et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): a multicenter, randomized phase II study (GOAL). Lung Cancer. 2020;150:62\u201369.","journal-title":"Lung Cancer"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S272563"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0718-5"},{"key":"e_1_3_4_103_1","first-page":"4880355","article-title":"Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy","volume":"2022","author":"Jin C","year":"2022","unstructured":"Jin C, Yuan M, Bu H, Jin C. Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy. J Oncol. 2022;2022:4880355\u20134880315.","journal-title":"J Oncol"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1156857"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-4121"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0294"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.020"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00683"},{"issue":"1","key":"e_1_3_4_109_1","doi-asserted-by":"crossref","first-page":"e041463","DOI":"10.1136\/bmjopen-2020-041463","article-title":"Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol","volume":"11","author":"Mansouri A","year":"2021","unstructured":"Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S. Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol. BMJ Open. 2021;11(1):e041463.","journal-title":"BMJ Open"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S369175"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S291267"},{"issue":"3","key":"e_1_3_4_112_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers11030413","article-title":"New phosphorylation sites of Rad51 by c-Met modulates presynaptic filament stability","volume":"11","author":"Chabot T","year":"2019","unstructured":"Chabot T, Defontaine A, Marquis D, Renodon-Corniere A, Courtois E, Fleury F, Cheraud Y. New phosphorylation sites of Rad51 by c-Met modulates presynaptic filament stability. Cancers (Basel). 2019;11(3):413.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_4_113_1","doi-asserted-by":"crossref","first-page":"1149918","DOI":"10.3389\/fmed.2023.1149918","article-title":"The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma","volume":"10","author":"Sabbah M","year":"2023","unstructured":"Sabbah M, Najem A, Vanderkerkhove C, Kert F, Jourani Y, Journe F, Awada A, Van Gestel D, Ghanem GE, Krayem M. The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma. Front Med (Lausanne). 2023;10:1149918.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010173"},{"issue":"6","key":"e_1_3_4_115_1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/s41419-021-03805-6","article-title":"BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair","volume":"12","author":"Zhang S","year":"2021","unstructured":"Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, et al. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021;12(6):546.","journal-title":"Cell Death Dis"},{"issue":"2","key":"e_1_3_4_116_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00432-019-03078-9","article-title":"Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib","volume":"146","author":"Eismann J","year":"2020","unstructured":"Eismann J, Heng YJ, Waldschmidt JM, Vlachos IS, Gray KP, Matulonis UA, Konstantinopoulos PA, Murphy CJ, Nabavi S, Wulf GM. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. J Cancer Res Clin Oncol. 2020;146(2):503\u2013514.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"e_1_3_4_117_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1389450122666210617111304","article-title":"Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer","volume":"23","author":"Shen K","year":"2022","unstructured":"Shen K, Yang L, Li FY, Zhang F, Ding LL, Yang J, Lu J, Wang NN, Wang Y. Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer. Curr Drug Targets. 2022;23(2):145\u2013155.","journal-title":"Curr Drug Targets"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3045"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.26"},{"issue":"17","key":"e_1_3_4_120_1","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner NC","year":"2024","unstructured":"Turner NC, Im SA, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391(17):1584\u20131596.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_4_121_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13046-021-01930-w","article-title":"Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer","volume":"40","author":"Zhu X","year":"2021","unstructured":"Zhu X, Chen L, Huang B, Li X, Yang L, Hu X, Jiang Y, Shao Z, Wang Z. Efficacy and mechanism of the combination of PARP and CDK4\/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40(1):122.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.11.011"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050340"},{"issue":"3","key":"e_1_3_4_124_1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.20517\/cdr.2023.08","article-title":"The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities","volume":"6","author":"Zielli T","year":"2023","unstructured":"Zielli T, Labidi-Galy I, Del Grande M, Sessa C, Colombo I. The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities. Cancer Drug Resist. 2023;6(3):499\u2013516.","journal-title":"Cancer Drug Resist"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061376"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0915-9"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00216"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.12.078"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117970"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14102"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249595"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116129"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1063"},{"issue":"1","key":"e_1_3_4_134_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","article-title":"Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia","volume":"12","author":"Gu S","year":"2023","unstructured":"Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12(1):23.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"e_1_3_4_135_1","doi-asserted-by":"crossref","first-page":"e18342","DOI":"10.1111\/jcmm.18342","article-title":"New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma","volume":"28","author":"Meneceur S","year":"2024","unstructured":"Meneceur S, De Vos CE, Petzsch P, K\u00f6hrer K, Niegisch G, Hoffmann MJ. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. J Cell Mol Med. 2024;28(9):e18342.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"e_1_3_4_136_1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12967-025-06544-w","article-title":"Inhibition of histone deacetylases 3 attenuates imiquimod-induced psoriatic dermatitis via targeting cGAS-STING signaling in keratinocytes","volume":"23","author":"Zeng C","year":"2025","unstructured":"Zeng C, Wen X, Wei Z, Dong X. Inhibition of histone deacetylases 3 attenuates imiquimod-induced psoriatic dermatitis via targeting cGAS-STING signaling in keratinocytes. J Transl Med. 2025;23(1):609.","journal-title":"J Transl Med"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00937-8"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.311"},{"issue":"7","key":"e_1_3_4_140_1","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.7150\/thno.41219","article-title":"ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma","volume":"10","author":"Han B","year":"2020","unstructured":"Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, Zha C, Ye Q, Jiang C, Cai J, et al. ATRX\/EZH2 complex epigenetically regulates FADD\/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 2020;10(7):3351\u20133365.","journal-title":"Theranostics"},{"issue":"48","key":"e_1_3_4_141_1","doi-asserted-by":"crossref","first-page":"eadl2804","DOI":"10.1126\/sciadv.adl2804","article-title":"EZH2 directly methylates PARP1 and regulates its activity in cancer","volume":"10","author":"Meng Q","year":"2024","unstructured":"Meng Q, Shen J, Ren Y, Liu Q, Wang R, Li Q, Jiang W, Wang Q, Zhang Y, Trinidad JC, et al. EZH2 directly methylates PARP1 and regulates its activity in cancer. Sci Adv. 2024;10(48):eadl2804.","journal-title":"Sci Adv"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2019.1595279"},{"issue":"13","key":"e_1_3_4_143_1","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1021\/acs.jmedchem.0c00208","article-title":"Preclinical lead optimization of a 1,2,4-triazole based Tankyrase inhibitor","volume":"63","author":"Waaler J","year":"2020","unstructured":"Waaler J, Leenders RGG, Sowa ST, Alam Brinch S, Lycke M, Nieczypor P, Aertssen S, Murthy S, Galera-Prat A, Damen E, et al. Preclinical lead optimization of a 1,2,4-triazole based Tankyrase inhibitor. J Med Chem. 2020;63(13):6834\u20136846.","journal-title":"J Med Chem"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12320"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00281"},{"issue":"1","key":"e_1_3_4_146_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41698-024-00757-w","article-title":"Targeting ErbB and tankyrase1\/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer","volume":"8","author":"Fujimura T","year":"2024","unstructured":"Fujimura T, Furugaki K, Mizuta H, Muraoka S, Nishio M, Adachi J, Uchibori K, Miyauchi E, Hayashi H, Katayama R, et al. Targeting ErbB and tankyrase1\/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. NPJ Precis Oncol. 2024;8(1):264.","journal-title":"NPJ Precis Oncol"},{"key":"e_1_3_4_147_1","doi-asserted-by":"crossref","first-page":"970553","DOI":"10.3389\/fphar.2022.970553","article-title":"Review of various NAMPT inhibitors for the treatment of cancer","volume":"13","author":"Wei Y","year":"2022","unstructured":"Wei Y, Xiang H, Zhang W. Review of various NAMPT inhibitors for the treatment of cancer. Front Pharmacol. 2022;13:970553.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1121"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201201250"},{"issue":"1","key":"e_1_3_4_150_1","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1186\/s12885-025-14568-0","article-title":"Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866","volume":"25","author":"Sha X","year":"2025","unstructured":"Sha X, Li J, Fang Y, Feng J, Feng Y, Wang J, Si Y, Li F, Cheng S, Ding W. Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866. BMC Cancer. 2025;25(1):1174.","journal-title":"BMC Cancer"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01281-8"},{"issue":"2","key":"e_1_3_4_152_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1574892815666200401113805","article-title":"Bortezomib - first therapeutic proteasome inhibitor for cancer therapy: a review of patent literature","volume":"15","author":"Vora PA","year":"2020","unstructured":"Vora PA, Patel R, Dharamsi A. Bortezomib - first therapeutic proteasome inhibitor for cancer therapy: a review of patent literature. Recent Pat Anticancer Drug Discov. 2020;15(2):113\u2013131.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2023.194979"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.07.008"},{"key":"e_1_3_4_155_1","first-page":"101781","article-title":"Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib","volume":"39","author":"Deng K","year":"2024","unstructured":"Deng K, Li Q, Lu L, Wang L, Cheng Z, Wang S. Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib. Biochem Biophys Rep. 2024;39:101781.","journal-title":"Biochem Biophys Rep"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"issue":"2","key":"e_1_3_4_157_1","doi-asserted-by":"crossref","first-page":"111081","DOI":"10.1016\/j.celrep.2022.111081","article-title":"Guiding ATR and PARP inhibitor combinationswith chemogenomic screens","volume":"40","author":"Zimmermann M","year":"2022","unstructured":"Zimmermann M, Bernier C, Kaiser B, Fournier S, Li L, Desjardins J, Skeldon A, Rimkunas V, Veloso A, Young JTF, et al. Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. Cell Rep. 2022;40(2):111081.","journal-title":"Cell Rep"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16217"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188633"},{"issue":"15","key":"e_1_3_4_160_1","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington SL","year":"2023","unstructured":"Wethington SL, Shah PD, Martin L, Tanyi JL, Latif N, Morgan M, Torigian DA, Rodriguez D, Smith SA, Dean E, et al. Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin Cancer Res. 2023;29(15):2800\u20132807.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_161_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Ror\u00e0 A","year":"2020","unstructured":"Ghelli Luserna di Ror\u00e0 A, Cerchione C, Martinelli G, Simonetti G. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 2020;13(1):126.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"e_1_3_4_162_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4143\/crt.2021.473","article-title":"Inhibition of WEE1 potentiates sensitivity to PARP inhibitor in biliary tract cancer","volume":"54","author":"Seo HR","year":"2022","unstructured":"Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY. Inhibition of WEE1 potentiates sensitivity to PARP inhibitor in biliary tract cancer. Cancer Res Treat. 2022;54(2):541\u2013553.","journal-title":"Cancer Res Treat"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0568"},{"issue":"1","key":"e_1_3_4_164_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41523-023-00568-5","article-title":"Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer","volume":"9","author":"Teo ZL","year":"2023","unstructured":"Teo ZL, O\u2019Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, Kuykhoven K, Mintoff CP, Savas P, Virassamy B, et al. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1\/2 wildtype triple-negative breast cancer. NPJ Breast Cancer. 2023;9(1):68.","journal-title":"NPJ Breast Cancer"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14184"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179134"},{"key":"e_1_3_4_167_1","doi-asserted-by":"crossref","first-page":"110475","DOI":"10.1016\/j.radonc.2024.110475","article-title":"Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Pol\u03b8 inhibition","volume":"200","author":"Lin X","year":"2024","unstructured":"Lin X, Soni A, Hessenow R, Sun Y, Mladenov E, Guberina M, Stuschke M, Iliakis G. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Pol\u03b8 inhibition. Radiother Oncol. 2024;200:110475.","journal-title":"Radiother Oncol"},{"issue":"1","key":"e_1_3_4_168_1","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1038\/s41467-023-43677-2","article-title":"Mechanisms of synthetic lethality between BRCA1\/2 and 53BP1 deficiencies and DNA polymerase theta targeting","volume":"14","author":"Ronson GE","year":"2023","unstructured":"Ronson GE, Starowicz K, Anthony EJ, Piberger AL, Clarke LC, Garvin AJ, Beggs AD, Whalley CM, Edmonds MJ, Beesley JFJ, et al. Mechanisms of synthetic lethality between BRCA1\/2 and 53BP1 deficiencies and DNA polymerase theta targeting. Nat Commun. 2023;14(1):7834.","journal-title":"Nat Commun"},{"key":"e_1_3_4_169_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0715"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy099"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad023"},{"issue":"6","key":"e_1_3_4_172_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/2767-9764.CRC-22-0485","article-title":"NCI 7977: a Phase I dose-escalation study of intermittent oral ABT-888 (Veliparib) plus Intravenous irinotecan administered in patients with advanced solid tumors","volume":"3","author":"Cecchini M","year":"2023","unstructured":"Cecchini M, Walther Z, Wei W, Hafez N, Pilat MJ, Boerner SA, Durecki DE, Eder JP, Schalper KA, Chen AP, et al. NCI 7977: a Phase I dose-escalation study of intermittent oral ABT-888 (Veliparib) plus Intravenous irinotecan administered in patients with advanced solid tumors. Cancer Res Commun. 2023;3(6):1113\u20131117.","journal-title":"Cancer Res Commun"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00438-2"},{"issue":"1","key":"e_1_3_4_174_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13148-024-01787-8","article-title":"BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine","volume":"16","author":"Panagopoulou M","year":"2024","unstructured":"Panagopoulou M, Panou T, Gkountakos A, Tarapatzi G, Karaglani M, Tsamardinos I, Chatzaki E. BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine. Clin Epigenetics. 2024;16(1):178.","journal-title":"Clin Epigenetics"},{"issue":"34","key":"e_1_3_4_175_1","doi-asserted-by":"crossref","first-page":"28745","DOI":"10.1074\/jbc.M112.351379","article-title":"Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo","volume":"287","author":"Kandala PK","year":"2012","unstructured":"Kandala PK, Srivastava SK. Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem. 2012;287(34):28745\u201328754.","journal-title":"J Biol Chem"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.09.005"},{"issue":"19","key":"e_1_3_4_177_1","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.7150\/thno.96879","article-title":"Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer","volume":"14","author":"Qiu Z","year":"2024","unstructured":"Qiu Z, Sigh D, Liu Y, Prasad CB, Bean N, Yan C, Li Z, Zhang X, Narla G, DiFeo A, et al. Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. Theranostics. 2024;14(19):7450\u20137469.","journal-title":"Theranostics"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.02.014"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab1184"},{"issue":"9","key":"e_1_3_4_180_1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/1078-0432.CCR-20-0468","article-title":"Disruption of DNA repair and survival pathways through heat shock protein inhibition by onalespib to sensitize malignant gliomas to chemoradiation therapy","volume":"28","author":"Xu J","year":"2022","unstructured":"Xu J, Wu PJ, Lai TH, Sharma P, Canella A, Welker AM, Beattie CE, Elder JB, Easley M, Lonser R, et al. Disruption of DNA repair and survival pathways through heat shock protein inhibition by onalespib to sensitize malignant gliomas to chemoradiation therapy. Clin Cancer Res. 2022;28(9):1979\u20131990.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"e_1_3_4_181_1","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/cas.70058","article-title":"Pimitespib, an HSP90 inhibitor, enhances the efficacy of PARP inhibitors in PARP inhibitor-insensitive breast cancer cells","volume":"116","author":"Muraoka H","year":"2025","unstructured":"Muraoka H, Kazuno H, Hashimoto A, Sootome H, Ohkubo S. Pimitespib, an HSP90 inhibitor, enhances the efficacy of PARP inhibitors in PARP inhibitor-insensitive breast cancer cells. Cancer Sci. 2025;116(6):1745\u20131757.","journal-title":"Cancer Sci"},{"issue":"1","key":"e_1_3_4_182_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00384-024-04654-3","article-title":"PD-1\/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review","volume":"39","author":"Wu H","year":"2024","unstructured":"Wu H, Deng M, Xue D, Guo R, Zhang C, Gao J, Li H. PD-1\/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review. Int J Colorectal Dis. 2024;39(1):83.","journal-title":"Int J Colorectal Dis"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01242-2"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02849-z"},{"issue":"5","key":"e_1_3_4_186_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3892\/mmr.2021.12001","article-title":"A combination of PD1\/PDL1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy (Review)","volume":"23","author":"Kong X","year":"2021","unstructured":"Kong X, Lu P, Liu C, Guo Y, Yang Y, Peng Y, Wang F, Bo Z, Dou X, Shi H, et al. A combination of PD1\/PDL1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy (Review). Mol Med Rep. 2021;23(5):362.","journal-title":"Mol Med Rep"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-2531"},{"issue":"2","key":"e_1_3_4_188_1","doi-asserted-by":"crossref","first-page":"e010511","DOI":"10.1136\/jitc-2024-010511","article-title":"Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors","volume":"13","author":"Luke JJ","year":"2025","unstructured":"Luke JJ, Pinato DJ, Juric D, LoRusso P, Hosein PJ, Desai AM, Haddad R, de Miguel M, Cervantes A, Kim WS, et al. Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J Immunother Cancer. 2025;13(2):e010511.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"e_1_3_4_189_1","doi-asserted-by":"crossref","first-page":"e011572","DOI":"10.1136\/jitc-2025-011572","article-title":"Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies","volume":"13","author":"Jacoby J","year":"2025","unstructured":"Jacoby J, Mahalingam D, Alistar A, Garmey E, Kazmi S, Mooneyham T, Sun L, Yap TA, Vu P, Moser J. Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies. J Immunother Cancer. 2025;13(6):e011572.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001643"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09021-y"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003"},{"issue":"10","key":"e_1_3_4_194_1","doi-asserted-by":"crossref","first-page":"oyaf270","DOI":"10.1093\/oncolo\/oyaf270","article-title":"Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer","volume":"30","author":"Rimel BJ","year":"2025","unstructured":"Rimel BJ, Pujade-Lauraine E, Moore K, Pfisterer J, Han S, Cibula D, Reyners A, Redondo A, Papadimitriou C, Eitan R, et al. Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer. Oncologist. 2025;30(10):oyaf270.","journal-title":"Oncologist"},{"key":"e_1_3_4_195_1","doi-asserted-by":"crossref","first-page":"638295","DOI":"10.3389\/fonc.2021.638295","article-title":"Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"11","author":"Ren N","year":"2021","unstructured":"Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M. Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:638295.","journal-title":"Front Oncol"},{"issue":"10","key":"e_1_3_4_196_1","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.7150\/ijbs.93697","article-title":"Using combination therapy to overcome diverse challenges of immune checkpoint inhibitors treatment","volume":"20","author":"Birnboim-Perach R","year":"2024","unstructured":"Birnboim-Perach R, Benhar I. Using combination therapy to overcome diverse challenges of immune checkpoint inhibitors treatment. Int J Biol Sci. 2024;20(10):3911\u20133922.","journal-title":"Int J Biol Sci"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.03.006"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0467"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-15-0191-T"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1223"},{"key":"e_1_3_4_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.41"},{"key":"e_1_3_4_202_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1546"},{"key":"e_1_3_4_203_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2796"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30684-9"},{"issue":"1","key":"e_1_3_4_206_1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1186\/s12885-022-10432-7","article-title":"Increased HRD score in cisplatin resistant penile cancer cells","volume":"22","author":"Winkelmann R","year":"2022","unstructured":"Winkelmann R, Bankov K, D\u00f6ring C, Cinatl J, Grothe S, Rothweiler F, Michaelis M, Schmitt C, Wild PJ, Demes M, et al. Increased HRD score in cisplatin resistant penile cancer cells. BMC Cancer. 2022;22(1):1352.","journal-title":"BMC Cancer"},{"issue":"8","key":"e_1_3_4_207_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jmoldx.2025.05.003","article-title":"Recommendations for clinical molecular laboratories for detection of homologous recombination deficiency in cancer: a joint consensus recommendation of the association for molecular pathology, Association of Cancer Care Centers, and College of American Pathologists","volume":"27","author":"Hsiao SJ","year":"2025","unstructured":"Hsiao SJ, Black D, Devereaux KA, Hagemann IS, Jennings LJ, Mandelker D, Paulson VA, Shiller M, Stockley TL, Vail E, et al. Recommendations for clinical molecular laboratories for detection of homologous recombination deficiency in cancer: a joint consensus recommendation of the association for molecular pathology, Association of Cancer Care Centers, and College of American Pathologists. J Mol Diagn. 2025;27(8):685\u2013704.","journal-title":"J Mol Diagn"},{"issue":"3","key":"e_1_3_4_208_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng S","year":"2022","unstructured":"Zheng S, Wang W, Aldahdooh J, Malyutina A, Shadbahr T, Tanoli Z, Pessia A, Tang J. SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022;20(3):587\u2013596.","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"1","key":"e_1_3_4_209_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang J","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_4_210_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2023-0192"},{"key":"e_1_3_4_211_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2024.2380243"},{"key":"e_1_3_4_212_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0292"},{"key":"e_1_3_4_213_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2018.04.001","article-title":"CRISPR\/Cas9 for cancer research and therapy","volume":"55","author":"Zhan T","year":"2019","unstructured":"Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M. CRISPR\/Cas9 for cancer research and therapy. Semin Cancer Biol. 2019;55:106\u2013119.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_4_214_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21859"},{"key":"e_1_3_4_215_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114551"},{"issue":"11","key":"e_1_3_4_216_1","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00018-019-03283-2","article-title":"Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration","volume":"77","author":"Sahaboglu A","year":"2020","unstructured":"Sahaboglu A, Miranda M, Canjuga D, Avci-Adali M, Savytska N, Secer E, Feria-Pliego JA, Kay\u0131k G, Durdagi S. Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration. Cell Mol Life Sci. 2020;77(11):2199\u20132216.","journal-title":"Cell Mol Life Sci"},{"key":"e_1_3_4_217_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114524"},{"key":"e_1_3_4_218_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114094"},{"key":"e_1_3_4_219_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01352"},{"key":"e_1_3_4_220_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115461"},{"key":"e_1_3_4_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106529"},{"key":"e_1_3_4_222_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117235"},{"key":"e_1_3_4_223_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.07.050"},{"issue":"2","key":"e_1_3_4_224_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cclet.2019.06.019","article-title":"Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents","volume":"31","author":"Dai QZ","year":"2020","unstructured":"Dai QZ, Chen JW, Gao CM, Sun QS, Yuan ZG, Jiang YY. Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents. Chin Chem Lett. 2020;31(2):404\u2013408.","journal-title":"Chin Chem Lett"},{"key":"e_1_3_4_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115598"},{"key":"e_1_3_4_226_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116348"},{"issue":"8","key":"e_1_3_4_227_1","first-page":"2649","article-title":"AMXI-5001, a novel dual parp1\/2 and microtubule polymerization inhibitor for the treatment of human cancers","volume":"10","author":"Lemjabbar-Alaoui H","year":"2020","unstructured":"Lemjabbar-Alaoui H, Peto CJ, Yang YW, Jablons DM. AMXI-5001, a novel dual parp1\/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020;10(8):2649\u20132676.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"e_1_3_4_228_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.62347\/UHLU6598","article-title":"Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy","volume":"14","author":"Brand NR","year":"2024","unstructured":"Brand NR, Yang YW, Ding V, Dutta H, Peto CJ, Lemjabbar-Alaoui H, Jablons DM. Novel dual action PARP and microtubule polymerization inhibitor AMXI-5001 powerfully inhibits growth of esophageal carcinoma both alone and in combination with radiotherapy. Am J Cancer Res. 2024;14(1):378\u2013389.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_229_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00932"},{"key":"e_1_3_4_230_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2276665"},{"key":"e_1_3_4_231_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(23)60429-7"},{"key":"e_1_3_4_232_1","doi-asserted-by":"crossref","first-page":"116739","DOI":"10.1016\/j.bmc.2022.116739","article-title":"Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers","volume":"61","author":"Lin S","year":"2022","unstructured":"Lin S, Zhang X, Yu Z, Huang X, Xu J, Liu Y, Wu L. Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers. Bioorg Med Chem. 2022;61:116739.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_4_233_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2RA03549A"},{"key":"e_1_3_4_234_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02008"},{"key":"e_1_3_4_235_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_4_236_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00885-3"},{"key":"e_1_3_4_237_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112981"},{"key":"e_1_3_4_238_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00649"},{"key":"e_1_3_4_239_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0"},{"issue":"1","key":"e_1_3_4_240_1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13045-021-01196-x","article-title":"VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status","volume":"14","author":"Bizzaro F","year":"2021","unstructured":"Bizzaro F, Fuso Nerini I, Taylor MA, Anastasia A, Russo M, Damia G, Guffanti F, Guana F, Ostano P, Minoli L, et al. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. J Hematol Oncol. 2021;14(1):186.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_4_241_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102224"},{"key":"e_1_3_4_242_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00640"},{"key":"e_1_3_4_243_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4032"},{"key":"e_1_3_4_244_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15655"},{"key":"e_1_3_4_245_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00077"},{"issue":"1","key":"e_1_3_4_246_1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-017-3639-0","article-title":"Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors","volume":"17","author":"Philip CA","year":"2017","unstructured":"Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017;17(1):638.","journal-title":"BMC Cancer"},{"key":"e_1_3_4_247_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00622"},{"key":"e_1_3_4_248_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113357"},{"key":"e_1_3_4_249_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113054"},{"issue":"4","key":"e_1_3_4_250_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41419-020-2408-1","article-title":"Pan-cancer analysis reveals synergistic effects of CDK4\/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells","volume":"11","author":"Li S","year":"2020","unstructured":"Li S, Zhang Y, Wang N, Guo R, Liu Q, Lv C, Wang J, Wang L, Yang QK. Pan-cancer analysis reveals synergistic effects of CDK4\/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death Dis. 2020;11(4):219.","journal-title":"Cell Death Dis"},{"key":"e_1_3_4_251_1","doi-asserted-by":"crossref","first-page":"106683","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"139","author":"Wang C","year":"2023","unstructured":"Wang C, Luo H, Chen X, Zhang Y, Lu D, Liu X, Yin F, Li S, Kong L, Wang X. Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA. Bioorg Chem. 2023;139:106683.","journal-title":"Bioorg Chem"},{"key":"e_1_3_4_252_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052892"},{"key":"e_1_3_4_253_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01058"},{"key":"e_1_3_4_254_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3785"},{"key":"e_1_3_4_255_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.10.077"},{"key":"e_1_3_4_256_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2022.2041783"},{"key":"e_1_3_4_257_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115648"},{"key":"e_1_3_4_258_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813769"},{"issue":"1","key":"e_1_3_4_259_1","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1038\/s41467-024-50158-7","article-title":"PARG is essential for Pol\u03b8-mediated DNA end-joining by removing repressive poly-ADP-ribose marks","volume":"15","author":"Vekariya U","year":"2024","unstructured":"Vekariya U, Minakhin L, Chandramouly G, Tyagi M, Kent T, Sullivan-Reed K, Atkins J, Ralph D, Nieborowska-Skorska M, Kukuyan AM, et al. PARG is essential for Pol\u03b8-mediated DNA end-joining by removing repressive poly-ADP-ribose marks. Nat Commun. 2024;15(1):5822.","journal-title":"Nat Commun"},{"key":"e_1_3_4_260_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23463-8"},{"key":"e_1_3_4_261_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.019"},{"key":"e_1_3_4_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.10.011"},{"key":"e_1_3_4_263_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal1645"},{"key":"e_1_3_4_264_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.06.003"},{"issue":"9","key":"e_1_3_4_265_1","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy","volume":"65","author":"Zhang J","year":"2022","unstructured":"Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, et al. Discovery of 4-hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy. J Med Chem. 2022;65(9):6803\u20136825.","journal-title":"J Med Chem"},{"key":"e_1_3_4_266_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01535"},{"key":"e_1_3_4_267_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114116"},{"issue":"19","key":"e_1_3_4_268_1","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.1021\/acs.jcim.4c01421","article-title":"Combining data-driven and structure-based approaches in designing dual PARP1-BRD4 inhibitors for breast cancer treatment","volume":"64","author":"Feng B","year":"2024","unstructured":"Feng B, Yu H, Dong X, D\u00edaz-Holgu\u00edn A, Antolin AA, Hu H. Combining data-driven and structure-based approaches in designing dual PARP1-BRD4 inhibitors for breast cancer treatment. J Chem Inf Model. 2024;64(19):7725\u20137742.","journal-title":"J Chem Inf Model"},{"issue":"1","key":"e_1_3_4_269_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin L","year":"2018","unstructured":"Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, et al. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res. 2018;37(1):153.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"e_1_3_4_270_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-020-01728-2","article-title":"The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer","volume":"39","author":"Ma L","year":"2020","unstructured":"Ma L, Bian X, Lin W. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. J Exp Clin Cancer Res. 2020;39(1):219.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_4_271_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666190603092407"},{"key":"e_1_3_4_272_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.05.058"},{"key":"e_1_3_4_273_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127036"},{"issue":"1","key":"e_1_3_4_274_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu Q","year":"2024","unstructured":"Zhu Q, Dai Q, Zhao L, Zheng C, Li Q, Yuan Z, Li L, Xie Z, Qiu Z, Huang W, et al. Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer. Cell Death Dis. 2024;15(1):10.","journal-title":"Cell Death Dis"},{"issue":"7","key":"e_1_3_4_275_1","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/ddr.70013","article-title":"PARP7i clinical candidate RBN-2397 exerts antiviral activity by modulating Interferon-\u03b2 associated innate immune response in macrophages","volume":"85","author":"Du X","year":"2024","unstructured":"Du X, Zhou J, Zhou Y, Chen Y, Kang Y, Zhao D, Ye XY, Wang L, Xie T, Zhang H. PARP7i clinical candidate RBN-2397 exerts antiviral activity by modulating Interferon-\u03b2 associated innate immune response in macrophages. Drug Dev Res. 2024;85(7):e70013.","journal-title":"Drug Dev Res"},{"key":"e_1_3_4_276_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107469"},{"key":"e_1_3_4_277_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00090"},{"issue":"17","key":"e_1_3_4_278_1","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-22-3897","article-title":"A bifunctional PARP-HDAC inhibitor with activity in Ewing sarcoma","volume":"29","author":"Ramos L","year":"2023","unstructured":"Ramos L, Truong S, Zhai B, Joshi J, Ghaidi F, Lizardo MM, Shyp T, Kung SHY, Rezakhanlou AM, Oo HZ, et al. A bifunctional PARP-HDAC inhibitor with activity in Ewing sarcoma. Clin Cancer Res. 2023;29(17):3541\u20133553.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_279_1","doi-asserted-by":"crossref","first-page":"965244","DOI":"10.3389\/fphar.2022.965244","article-title":"Combined inhibition of PARP and EZH2 for cancer treatment: current status, opportunities, and challenges","volume":"13","author":"Zhang X","year":"2022","unstructured":"Zhang X, Huo X, Guo H, Xue L. Combined inhibition of PARP and EZH2 for cancer treatment: current status, opportunities, and challenges. Front Pharmacol. 2022;13:965244.","journal-title":"Front Pharmacol"},{"key":"e_1_3_4_280_1","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2020.1760675"},{"key":"e_1_3_4_281_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00567"},{"key":"e_1_3_4_282_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116054"},{"issue":"1","key":"e_1_3_4_283_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13046-021-01950-6","article-title":"Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities","volume":"40","author":"Zamudio-Martinez E","year":"2021","unstructured":"Zamudio-Martinez E, Herrera-Campos AB, Mu\u00f1oz A, Rodr\u00edguez-Vargas JM, Oliver FJ. Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities. J Exp Clin Cancer Res. 2021;40(1):144.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_4_284_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5846"},{"issue":"12","key":"e_1_3_4_285_1","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.7150\/ijbs.113726","article-title":"JPI-547, a dual inhibitor of PARP\/Tankyrase, shows antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction","volume":"21","author":"Oh KS","year":"2025","unstructured":"Oh KS, Nam AR, Bang JH, Jeong Y, Choo SY, Kim HJ, Lee SI, Kim JM, Yoon J, Kim TY, et al. JPI-547, a dual inhibitor of PARP\/Tankyrase, shows antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction. Int J Biol Sci. 2025;21(12):5460\u20135475.","journal-title":"Int J Biol Sci"},{"issue":"15","key":"e_1_3_4_286_1","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2021.39.15_suppl.3113","article-title":"A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP\/tankyrase in patients with advanced solid tumors","volume":"39","author":"Im SA","year":"2021","unstructured":"Im SA, Lee S, Lee K, Lee Y, Sohn JH, Kim JH, Im Y, Park KH, Oh DY, Kim MH, et al. A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP\/tankyrase in patients with advanced solid tumors. JCO. 2021;39(15_suppl):3113\u20133113.","journal-title":"JCO"},{"key":"e_1_3_4_287_1","doi-asserted-by":"crossref","first-page":"114417","DOI":"10.1016\/j.ejmech.2022.114417","article-title":"Rational design, synthesis and biological evaluation of dual PARP-1\/2 and TNKS1\/2 inhibitors for cancer therapy","volume":"237","author":"Xu Y","year":"2022","unstructured":"Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q. Rational design, synthesis and biological evaluation of dual PARP-1\/2 and TNKS1\/2 inhibitors for cancer therapy. Eur J Med Chem. 2022;237:114417.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_288_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016573"},{"key":"e_1_3_4_289_1","doi-asserted-by":"crossref","first-page":"130117","DOI":"10.1016\/j.bmcl.2025.130117","article-title":"Discovery of dual PARP\/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer","volume":"120","author":"Mao J","year":"2025","unstructured":"Mao J, Wang K, Tong J, Zhang W, Shen G, Wang D, Liao Z, Zhang Z, Miao Q, Jiang S, et al. Discovery of dual PARP\/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer. Bioorg Med Chem Lett. 2025;120:130117.","journal-title":"Bioorg Med Chem Lett"},{"issue":"49","key":"e_1_3_4_290_1","doi-asserted-by":"crossref","first-page":"e2309047120","DOI":"10.1073\/pnas.2309047120","article-title":"PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis","volume":"120","author":"Manetsch P","year":"2023","unstructured":"Manetsch P, B\u00f6hi F, Nowak K, Leslie Pedrioli DM, Hottiger MO. PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis. Proc Natl Acad Sci U S A. 2023;120(49):e2309047120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"e_1_3_4_291_1","doi-asserted-by":"crossref","first-page":"e2424985122","DOI":"10.1073\/pnas.2424985122","article-title":"CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity","volume":"122","author":"Gorelik A","year":"2025","unstructured":"Gorelik A, Paulo JA, Schroeter CB, Lad M, Shurr A, Mastrokalou C, Siddiqi S, Suyari O, Brognard J, Walter D, et al. CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity. Proc Natl Acad Sci U S A. 2025;122(24):e2424985122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"e_1_3_4_292_1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","article-title":"PARP7 as a new target for activating anti-tumor immunity in cancer","volume":"17","author":"Popova K","year":"2025","unstructured":"Popova K, Benedum J, Engl M, L\u00fctgendorf-Caucig C, Fossati P, Widder J, Podar K, Slade D. PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Mol Med. 2025;17(5):872\u2013888.","journal-title":"EMBO Mol Med"},{"issue":"13","key":"e_1_3_4_293_1","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","article-title":"Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential cancer treatment","volume":"67","author":"Gao Y","year":"2024","unstructured":"Gao Y, Duan JL, Wang CC, Yuan Y, Zhang P, Wang ZH, Sun B, Zhou J, Du X, Dang X, et al. Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential cancer treatment. J Med Chem. 2024;67(13):10848\u201310874.","journal-title":"J Med Chem"},{"key":"e_1_3_4_294_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121789"},{"key":"e_1_3_4_295_1","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201900017"},{"key":"e_1_3_4_296_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.05.006"},{"key":"e_1_3_4_297_1","doi-asserted-by":"crossref","first-page":"115943","DOI":"10.1016\/j.ejmech.2023.115943","article-title":"Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer","volume":"264","author":"He H","year":"2024","unstructured":"He H, Yang W, Shi Y, Chen X, Chen X, Hu X, Li X, Yang Y, Liu Z, Ye T, et al. Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer. Eur J Med Chem. 2024;264:115943.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_298_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00558-5"},{"key":"e_1_3_4_299_1","doi-asserted-by":"crossref","first-page":"1414112","DOI":"10.3389\/fonc.2024.1414112","article-title":"Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer","volume":"14","author":"Kulkarni S","year":"2024","unstructured":"Kulkarni S, Gajjar K, Madhusudan S. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer. Front Oncol. 2024;14:1414112.","journal-title":"Front Oncol"},{"issue":"8","key":"e_1_3_4_300_1","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","article-title":"BRCAness, homologous recombination deficiencies, and synthetic lethality","volume":"83","author":"Murai J","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, homologous recombination deficiencies, and synthetic lethality. Cancer Res. 2023;83(8):1173\u20131174.","journal-title":"Cancer Res"},{"key":"e_1_3_4_301_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2997"},{"key":"e_1_3_4_302_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02745-0"},{"issue":"29","key":"e_1_3_4_303_1","doi-asserted-by":"crossref","first-page":"e01916","DOI":"10.1002\/advs.202501916","article-title":"Novel ATR\/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast cancer models","volume":"12","author":"Gao Y","year":"2025","unstructured":"Gao Y, Zhou J, Wang CC, Wang ZH, Mao ND, He ML, Zhang PP, Huang P, Ye GW, Zhang YQ, et al. Novel ATR\/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast cancer models. Adv Sci (Weinh). 2025;12(29):e01916.","journal-title":"Adv Sci (Weinh)"},{"key":"e_1_3_4_304_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.09.085"},{"key":"e_1_3_4_305_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2015.05.051"},{"key":"e_1_3_4_306_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1582646"},{"issue":"2","key":"e_1_3_4_307_1","doi-asserted-by":"crossref","first-page":"135761","DOI":"10.1016\/j.ijbiomac.2024.135761","article-title":"Exploring aldose reductase inhibitors as promising therapeutic targets for diabetes-linked disabilities","volume":"280","author":"Ahmad S","year":"2024","unstructured":"Ahmad S, Ahmad MFA, Khan S, Alouffi S, Khan M, Prakash C, Khan MWA, Ansari IA. Exploring aldose reductase inhibitors as promising therapeutic targets for diabetes-linked disabilities. Int J Biol Macromol. 2024;280(Pt 2):135761.","journal-title":"Int J Biol Macromol"},{"key":"e_1_3_4_308_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106108"},{"key":"e_1_3_4_309_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.04.038"},{"issue":"614","key":"e_1_3_4_310_1","doi-asserted-by":"crossref","first-page":"eabg6428","DOI":"10.1126\/scitranslmed.abg6428","article-title":"Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer","volume":"13","author":"Zhang KR","year":"2021","unstructured":"Zhang KR, Zhang YF, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y, Chen HZ, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Sci Transl Med. 2021;13(614):eabg6428.","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_311_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213954"},{"key":"e_1_3_4_312_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fnagi.2020.00255","article-title":"Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer\u2019s disease","volume":"12","author":"Salech F","year":"2020","unstructured":"Salech F, Ponce DP, Paula-Lima AC, SanMartin CD, Behrens MI. Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) inhibitor, as an adjunctive therapy for the treatment of Alzheimer\u2019s disease. Front Aging Neurosci. 2020;12:255.","journal-title":"Front Aging Neurosci"},{"key":"e_1_3_4_313_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081284"},{"key":"e_1_3_4_314_1","doi-asserted-by":"crossref","first-page":"116463","DOI":"10.1016\/j.ejmech.2024.116463","article-title":"Discovery of 4-benzylpiperazinequinoline BChE inhibitor that suppresses neuroinflammation for the treatment of Alzheimer\u2019s disease","volume":"272","author":"Chen Y","year":"2024","unstructured":"Chen Y, Zhang W, Li Q, Xie H, Xing S, Lu X, Lyu W, Xiong B, Wang Y, Qu W, et al. Discovery of 4-benzylpiperazinequinoline BChE inhibitor that suppresses neuroinflammation for the treatment of Alzheimer\u2019s disease. Eur J Med Chem. 2024;272:116463.","journal-title":"Eur J Med Chem"},{"key":"e_1_3_4_315_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2018.1530224"},{"key":"e_1_3_4_316_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.05.052"},{"key":"e_1_3_4_317_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.09.054"},{"key":"e_1_3_4_318_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-022-00747-1"},{"key":"e_1_3_4_319_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genet-021920-092410"},{"issue":"1","key":"e_1_3_4_320_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino T","year":"2023","unstructured":"Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14(1):252.","journal-title":"Nat Commun"},{"key":"e_1_3_4_321_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070981"},{"key":"e_1_3_4_322_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.4c00022"},{"issue":"6","key":"e_1_3_4_323_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12032-023-02042-5","article-title":"Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia","volume":"40","author":"Ishikawa C","year":"2023","unstructured":"Ishikawa C, Mori N. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia. Med Oncol. 2023;40(6):172.","journal-title":"Med Oncol"},{"issue":"9","key":"e_1_3_4_324_1","doi-asserted-by":"crossref","first-page":"115434","DOI":"10.1016\/j.bmc.2020.115434","article-title":"Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities","volume":"28","author":"Lin S","year":"2020","unstructured":"Lin S, Zhang L, Zhang X, Yu Z, Huang X, Xu J, Liu Y, Chen L, Wu L. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities. Bioorg Med Chem. 2020;28(9):115434.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_4_325_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6"},{"issue":"4","key":"e_1_3_4_326_1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal A","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30(4):969\u2013983.","journal-title":"Nat Med"},{"key":"e_1_3_4_327_1","doi-asserted-by":"crossref","first-page":"117936","DOI":"10.1016\/j.bmc.2024.117936","article-title":"Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA","volume":"113","author":"Liu Z","year":"2024","unstructured":"Liu Z, Mao S, Dai L, Huang R, Hu W, Yu C, Yang Y, Cao G, Huang X. Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA. Bioorg Med Chem. 2024;113:117936.","journal-title":"Bioorg Med Chem"},{"key":"e_1_3_4_328_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14101269"},{"key":"e_1_3_4_329_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2019.1654458"},{"key":"e_1_3_4_330_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557523666230221145844"},{"key":"e_1_3_4_331_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-1740-3_7","article-title":"Identification of synthetic lethal interactions using high-throughput, arrayed CRISPR\/Cas9-based platforms","volume":"2381","author":"MacAuley MJ","year":"2021","unstructured":"MacAuley MJ, Abuhussein O, Vizeacoumar FS. Identification of synthetic lethal interactions using high-throughput, arrayed CRISPR\/Cas9-based platforms. Methods Mol Biol. 2021;2381:135\u2013149.","journal-title":"Methods Mol Biol"},{"key":"e_1_3_4_332_1","doi-asserted-by":"crossref","first-page":"1295523","DOI":"10.3389\/fimmu.2023.1295523","article-title":"High-throughput CRISPR technology: a novel horizon for solid organ transplantation","volume":"14","author":"Li X","year":"2023","unstructured":"Li X, Chen Z, Ye W, Yu J, Zhang X, Li Y, Niu Y, Ran S, Wang S, Luo Z, et al. High-throughput CRISPR technology: a novel horizon for solid organ transplantation. Front Immunol. 2023;14:1295523.","journal-title":"Front Immunol"},{"key":"e_1_3_4_333_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00703-8"},{"key":"e_1_3_4_334_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05905-z"},{"key":"e_1_3_4_335_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103395"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2025.2598478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:02:32Z","timestamp":1765803752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2025.2598478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":334,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2025.2598478"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2025.2598478","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2598478"}}